In urothelial bladder cancer, hypomethylation of the CLDN4 promoter region was associated with cancer metastasis, and so hypermethylation of CLDN4 represents a new potential target of therapy for bladder cancer [141]. This evidence concerns the gene CLDN4 and bladder transitional cell carcinoma.